GlassScriptPhysician profile
Steven C Jones
NPI 1437170917
$11,600.60
in general payments reported to CMS, 2019-2025
43 companies · $1,562 in 2025
The $1,562 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,762 · 2020: $1,098 · 2021: $1,516 · 2022: $1,871 · 2023: $1,586 · 2024: $2,206 · 2025: $1,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,353.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,756.39 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,341.45 | 2019-2025 | Evenity, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,134.84 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $1,130.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,045.70 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $585.96 | 2019-2025 | |
| Abbvie INC. | $575.98 | 2019-2024 | |
| Amarin Pharma, INC. | $517.52 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $296.01 | 2021-2024 | |
| Kowa Pharmaceuticals America, INC. | $277.77 | 2020-2025 | Zoryve |
| Glaxosmithkline, LLC. | $199.36 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boston Scientific Corporation | $182.12 | 2024 | Watchman Flx |
| Abbott Laboratories | $180.15 | 2019-2025 | Freestyle Libre 3 |
| Eisai INC. | $175.20 | 2021-2025 | |
| Astellas Pharma US INC | $172.89 | 2019-2025 | Veozah |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,672,678.50 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.